跳至主要内容
临床试验/NCT07580950
NCT07580950招募中4 期

The Research of Integrated Traditional Chinese and Western Medicine on Hypothalamic Amenorrhea

Peking Union Medical College Hospital1 个研究点 分布在 1 个国家目标入组 210 人开始时间: 2025年10月22日最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
210
试验地点
1

研究概览

简要总结

This study aims to validate the efficacy and safety of the "two-step cycle-regulating approach integrating Chinese and Western medicine: rapid restoration of menstruation with Western medicine, and nourish the kidney and soothe the liver, nourishing the essence, and reinforcing the vital essence and strengthening the primordial qi with Chinese medicine" through a nationwide randomized controlled clinical trial involving 210 cases. Guided by traditional Chinese medicine theory, the study will explore the mechanism of integrated Chinese and Western medicine in the treatment of functional hypothalamic amenorrhea through gut microbiota and metabolomics research.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
14 Years 至 40 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • Diagnostic criteria for functional hypothalamic amenorrhea
  • primary or secondary amenorrhea
  • Normal or low FSH levels, LH < 5 IU/L, E2 < 50 pg/mL
  • Exclusion of amenorrhea caused by: -Organic lesions of the hypothalamus or pituitary gland , Ovarian amenorrhea , Uterine or lower genital tract developmental abnormalities ,Drug-induced amenorrhea ,Other causes of amenorrhea

排除标准

  • Individuals who have used relevant medications within the past 3 months
  • History of substance abuse or dependence (alcohol or drugs) within the past 3 months; heavy smokers (those consuming 20 or more cigarettes daily)
  • Individuals with severe or unstable physical illnesses, including liver, kidney, gastrointestinal, cardiovascular, cerebrovascular, respiratory, endocrine, neurological, immune, or hematological disorders; psychiatric patients
  • Lactating or pregnant women, or females within one year postpartum
  • History of allergy to the investigational drug; contraindications to Dingkundan, Bazhen Yimu Pills, or Femoston
  • Individuals with or suspected of having estrogen-sensitive tumors (e.g., endometrial cancer, breast cancer).
  • History of thromboembolic disease or thrombotic tendency.
  • Participation in another investigational drug clinical trial within 1 month prior to inclusion in this study (first interview).

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验